Mirae Asset Global Investments Co. Ltd. Cuts Position in Repligen Corporation $RGEN

Mirae Asset Global Investments Co. Ltd. lessened its holdings in Repligen Corporation (NASDAQ:RGEN) by 1.0% during the second quarter, Holdings Channel.com reports. The institutional investor owned 29,522 shares of the biotechnology company’s stock after selling 300 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $3,672,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alliance Wealth Advisors LLC UT lifted its stake in Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 89 shares during the last quarter. State of Michigan Retirement System lifted its stake in Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after purchasing an additional 100 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after purchasing an additional 100 shares during the last quarter. State of Wyoming lifted its stake in Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 115 shares during the last quarter. Finally, Signaturefd LLC lifted its stake in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on RGEN. HSBC began coverage on Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price objective on the stock. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research note on Sunday, June 29th. Jefferies Financial Group dropped their price objective on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, September 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Repligen in a report on Saturday, September 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus target price of $169.62.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.20% of the company’s stock.

Repligen Price Performance

Repligen stock opened at $145.93 on Wednesday. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The business has a fifty day moving average price of $123.40 and a 200-day moving average price of $125.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a market capitalization of $8.21 billion, a P/E ratio of -583.70, a PEG ratio of 2.77 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.